Title of Invention: HETEROCYCLIC OXIME COMPOUNDS Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I). Detailed Description: This application claims benefit under 35 U.S.C. §119(a)-(d) or (f) or 365(b) of U.S. Provisional Application 61/235,440, filed 20 Aug. 2009, and Chinese applications PCT/CN10/071,978, filed 21 Apr. 2010, and PCT/CN10/074,089, filed 18 Jun. 2010, the contents of which are incorporated herein by reference in their entirety. BACKGROUND OF THE INVENTION The Hepatocyte Growth Factor Receptor, herein referred to as c-Met, is a receptor tyrosine kinase that has been shown to be over-expressed and/or genetically altered in a variety of malignancies, specifically, gene amplification, and a number of c-Met mutations are found in various solid tumors, see e.g. WO2007/126799. Further, the receptor tyrosine kinase c-Met is involved in the processes of migration, invasion and morphogenesis that accompany embryogenesis and tissue regeneration. C-Met is also involved in the process of metastasis. Several lines of evidence have indicated that c-Met plays a role in tumor pathogenesis. Gain of function germ line mutations in c-Met is associated with development of hereditary papillary renal cell carcinoma (PRCC). Amplification or mutations in c-Met have also been reported in sporadic forms of PRCC, in head and neck squamous cell carcinoma, in gastric carcinoma, in pancreatic carcinoma and in lung cancer. Such alterations have been shown in selected instances to confer dependence of the tumor on c-Met and/or resistance to other targeted therapies. Elevated levels of c-Met, together with its unique ligand HGF/SF, are observed at high frequency in multiple clinically relevant tumors. A correlation between increased expression and disease progression, metastases and patient mortality has been reported in several cancers, including bladder, breast, squamous cell carcinoma and gastric carcinoma as well as leiomyosarcoma and glioblastoma. WO 2008/008539 discloses certain fused heterocyclic derivatives which are useful in the treatment of HGF mediated diseases. WO 2007/013673 discloses fused heterocyclic derivatives as Lck inhibitors which are useful as immunosuppressive agents. EP0490587 discloses certain pyrazolopyrimidines which are useful as angiotensin II antagonists. The disclosures of the publications cited in this specification are herein incorporated by reference. BRIEF SUMMARY OF THE INVENTION The invention relates to bicyclic compounds of formula (I) and salts thereof, the uses of such compounds to treat the human or animal body, in particular with regard to a proliferative disease, pharmaceutical compositions comprising such compounds, combinations comprising a compound of formula (I), and processes for the preparation of such compounds. BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS FIG. 1. X-ray diffractogram of Example 53S amorphous form. FIG. 2. X-ray diffractogram of Example 53S crystalline form I. FIG. 3. X-ray diffractogram of Example 53S crystalline form II. DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a compound of the formula (I) wherein Y is C or N; X is CH or N; B is CH or N; A is a ring; such that when X is CH and B is N, ring A is ring Ai or ring Aii; when X is N and B is N, ring A is Aiii; and when X is N and B is N, or X is N and B is CH, ring A is Ai; R1 is a group selected from i, ii and iii: wherein R5 is heteroaryl1, R6 is hydrogen, deuterium, OH, methyl or halo; R7 is hydrogen, deuterium, halo, or (C1-C3)alkyl, wherein said (C1-C3)alkyl is optionally substituted by one or more substituents independently selected from OH and halo; or R6 and R7, together with the carbon to which they are attached, form cyclopropyl; n is 0, 1 or 2; R2 is hydrogen, NH2, or (C1-C4)alkyl, wherein said (C1-C4)alkyl is optionally substituted by one or more substituents independently selected from OH, NH3 and halo; and R3 is (C1-C6)alkyl, wherein said (C1-C6)alkyl is optionally substituted by one or more substituents independently selected from halo, hydroxy and (C1-C3)alkoxy, heterocyclyl1 phenyl, wherein said phenyl is optionally substituted by one or more substituents independently selected from halo, hydroxy, (C1-C3)alkyl and (C1-C3)alkoxy, wherein said (C1-C3)alkyl and (C1-C3)alkoxy are each optionally substituted by one or more halo substituents, —CH2— heterocyclyl1 —CH2-phenyl, wherein the phenyl of said —CH2-phenyl is optionally substituted by one or more substituents independently selected from halo, hydroxy, (C1-C3)alkyl and (C1-C3)alkoxy, wherein said (C1-C3)alkyl and (C1-C3)alkoxy are each optionally substituted by one or more halo substituents, (C1-C4)alkylCO2(C1-C2)alkyl, (C0-C4)alkylCONH2, (C1-C4)alkylNH2, (C1-C4)alkylNHCONH2, (C1-C4)alkylCO2H, (C1-C4)alkylNHCO2CH3, —(C0-C4)alkyl(C3-C6)cycloalkyl or —(C0-C4)alkyl(C4-C6)cycloalkenyl, or Hydrogen, or a pharmaceutically acceptable salt thereof. It is an aim of the present invention to provide further compounds that modulate, and in particular inhibit, c-Met. It has now been found that the compounds of the formula (I) described herein are inhibitors of c-Met and have a number of therapeutic applications. For example, the compounds of formula (I) are suitable for use in the treatment of diseases dependent on c-Met activity, especially solid tumors or metastasis derived therefrom. Through the inhibition of c-Met, compounds of the invention also have utility as anti-inflammatory agents, for example for the treatment of an inflammatory condition which is due to an infection. Preferably, the compounds of the invention are metabolically stable, are non-toxic and demonstrate few side-effects. In addition, preferred compounds of the invention exist in a physical form that is stable, non-hygroscopic and easily formulated. One aspect of the invention is directed to compounds of formula (I) having an activity that is superior to the activity of compounds of the prior art, or other similar compounds. Another aspect of the invention is directed to compounds of formula (I) having good kinase selectivity. Preferred compounds of the invention posses favourable pharmacokinetic properties, such as good in-vivo exposure and/or solubility. The following general definitions shall apply in this specification, unless otherwise specified: A “compound of the invention”, or “compounds of the invention”, or “a compound of the present invention” means a compound or compounds of formula (I) as described herein. As used herein, the terms “including”, “containing” and “comprising” are used herein in their open, non-limiting sense. Where the plural form (e.g. compounds, salts) is used, this includes the singular (e.g. a single compound, a single salt). “A compound” does not exclude that (e.g. in a pharmaceutical formulation) more than one compound of the formula (I) (or a salt thereof) is present. “Treatment” includes prophylactic (preventive) and therapeutic treatment as well as the delay of progression of a disease, disorder or condition. Any non-cyclic carbon containing group or moiety with more than 1 carbon atom is straight-chain or branched. “Alkyl” refers to a straight-chain or branched-chain alkyl group. For example, (C1-C4)alkyl includes methyl, ethyl, n- or iso-propyl, and n-, iso-, sec- or tert-butyl. Heteroaryl1 is a 9- or 10-membered, unsaturated or partially unsaturated bicyclic group comprising 1, 2, 3 or 4 ring heteroatoms independently selected from N, O and S, wherein the total number of ring S atoms does not exceed 1, and the total number of ring O atoms does not exceed 1, wherein heteroaryl1 is optionally substituted by one or more substituents, preferably 1, 2 or 3 substituents, independently selected from: halo, OH, (C1-C3)alkyl, said (C1-C3)alkyl being optionally substituted by one or more substituents independently selected from OH and halo, heterocyclyl2, —C(CH3)═NO(C1-C3)alkyl, wherein the (C1-C3)alkyl of said C(CH3)═NO(C1-C3)alkyl is optionally substituted by one or more substituents independently selected from OH and halo. In another embodiment, heteroaryl1 is optionally substituted by one or more substituents, preferably 1, 2 or 3 substituents, independently selected from: halo, OH, (C1-C3)alkyl, said (C1-C3)alkyl being optionally substituted by one or more substituents independently selected from OH and halo, and —C(CH3)═NO(C1-C3)alkyl, wherein the (C1-C3)alkyl of said C(CH3)═NO(C1-C3)alkyl is optionally substituted by one or more substituents independently selected from OH and halo. Specific examples of heteroaryl1 include, but are not limited to, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, 1,5-naphthyridinyl, 1,6-naphthyridinyl, 1,7-naphthyridinyl, 1,8-naphthyridinyl, 2,6-naphthyridinyl, 2,7-naphthyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[4,3-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, pyrido[2,3-b]pyrazinyl, pyrido[3,4-b]pyrazinyl, pyrimido[5,4-d]pyrimidinyl, pyrazino[2,3-b]pyrazinyl, pyrimido[4,5-d]pyrimidinyl, benzofuranyl, benzothiophenyl, indolyl, benzimidazolyl, benzoxazolyl, indazoyl, benzotriazolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrrolo[3,2-b]pyridinyl, imidazo[4,5-b]pyridinyl, imidazo[4,5-c]pyridinyl, pyrazolo[4,3-d]pyridinyl, pyrazolo[4,3-c]pyridinyl, pyrazolo[3,4-c]pyridinyl, pyrazolo[3,4-b]pyridinyl, isoindolyl, indazolyl, purinyl, indolizinyl, imidazo[1,2-a]pyridinyl, imidazo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrrolo[1,2-b]pyridazinyl and imidazo[1,2-c]pyrimidinyl, and the partially saturated equivalents thereof. “heteroaryl3” means a 9- or 10-membered, unsaturated or partially unsaturated bicyclic group comprising 1 or 2 ring N heteroatoms. Heteroaryl3 is optionally substituted by one or more substituents independently selected from: halo, OH, (C1-C3)alkyl, wherein said (C1-C3)alkyl is optionally substituted by one or more substituents independently selected from OH and halo. heterocyclyl2, and —C(CH3)═NO(C1-C3)alkyl, wherein the (C1-C3)alkyl of said C(CH3)═NO(C1-C3)alkyl is optionally substituted by one or more substituents independently selected from OH and halo, In another embodiment, heteroaryl3 is optionally substituted by one or more substituents independently selected from: halo, OH, (C1-C3)alkyl, wherein said (C1-C3)alkyl is optionally substituted by one or more substituents independently selected from OH and halo, and —C(CH3)═NO(C1-C3)alkyl, wherein the (C1-C3)alkyl of said C(CH3)═NO(C1-C3)alkyl is optionally substituted by one or more substituents independently selected from OH and halo. Specific examples of heteroaryl3 include, but are not limited to, quinolinyl, isoquinolinyl, cinnolinyl, azaquinazolinyl, quinoxalinyl, phthalazinyl, 1,5-naphthyridinyl, 1,6-naphthyridinyl, 1,7-naphthyridinyl, 1,8-naphthyridinyl, 2,6-naphthyridinyl, 2,7-naphthyridinyl, indolyl, benzimidazolyl, indazolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrrolo[3,2-b]pyridinyl, isoindolyl, indazolyl, indolininyl, imidazo[1,2-a]pyridinyl, imidazo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyridinyl and pyrrolo[1,2-b]pyridazinyl. “heterocyclyl1” means a 4, 5 or 6 membered saturated or partially unsaturated monocyclic group comprising 1 or 2 ring heteroatoms independently selected from N, O and S. Heterocyclyl1 is optionally substituted by CONH2 or (C1-C3)alkyl. Specific examples of heterocyclyl1 include, but are not limited to, oxetanyl, thiatanyl, azetidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, 1,2,3,4-tetrahydropyridinyl, 1,2,5,6-tetrahydropyridinyl, pyrrolidinyl, piperidinyl and piperazinyl. “heterocyclyl2” means a 5 or 6 membered saturated, unsaturated or partially unsaturated monocyclic group comprising 1, 2 or 3 ring heteroatoms independently selected from N, O and S, wherein the total number of ring S atoms does not exceed 1, and the total number of ring O atoms does not exceed 1. Heterocyclyl2 is optionally substituted by (C1-C3)alkyl. Specific examples of heterocyclyl2 include, but are not limited to, tetrahydrofuranyl, tetrahydrothiophenyl, 1,2,3,4-tetrahydropyridinyl, 1,2,5,6-tetrahydropyridinyl, pyrrolidinyl, piperidinyl, piperazinyl, pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, 1,2,3-triazolyl, 1,3,4-triazolyl, 1-oxa-2,3-diazolyl, 1-oxa-2,4-diazolyl, 1-oxa-2,5-diazolyl, 1-oxa-3,4-diazolyl, 1-thia-2,3-diazolyl, 1-thia-2,4-diazolyl, 1-thia-2,5-diazolyl, 1-thia-3,4-diazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 3,4-dihydro-2H-pyranyl, 5,6-dihydro-2H-pyranyl and 2H-pyranyl. “disease” as used herein includes a disorder or condition. Halo means fluoro, chloro, bromo or iodo. In a particular embodiment of the invention, halo is fluoro or chloro. Preferably, halo is fluoro. According to the disclosures herein, the compound of formula (I) is selected from any one of the following structures (Ia) to (Ie): In an embodiment of the invention, there is provided a compound of formula (I) wherein B is N; Y is C or N; X is CH or N; such that when X is CH, ring A is ring Ai or ring Aii when X is N, ring A is Aiii; and when X is N and B is CH, ring A is Ai. Such compounds have the structure (Ia), (Ib), (Ic) or (Ie) as disclosed herein. In another embodiment of the invention, there is provided a compound of formula (I) wherein B is N; Y is C or N; X is CH or N; such that when X is CH, ring A is ring Ai or ring Aii and when X is N, ring A is Aiii; Such compounds have the structure (Ia), (Ib) or (Ic) as disclosed herein In a particular embodiment of the invention there is provided a compound having formula (Ib), wherein the substituents are as defined herein. In another embodiment of the invention, R1 is i or ii: In a preferred embodiment of the invention, R1 is i: In another embodiment of the invention, R1 is a group selected from i, ii and iii: and R5 is heteroaryl3. In another embodiment of the invention, R1 is i: and R5 is heteroaryl3. In another embodiment of the invention, heteroaryl1 and heteroaryl3 are each optionally substituted by one or more substituents independently selected from halo, 4-methylpiperazin-1-yl, ethanone O-(2-hydroxyethyl)oxime and (C1-C2)alkyl. In a preferred embodiment of the invention, R5 is indazolyl or quinolinyl, each optionally substituted by one or more substituents independently selected from halo, (C1-C3)alkyl, 4-methylpiperazin-1-yl and ethanone O-(2-hydroxyethyl)oxime. In particular, R5 is indazolyl or quinolinyl optionally substituted by one, two or three substituents independently selected from halo and (C1-C3)alkyl. In a further preferred embodiment of the invention, R5 is indazolyl optionally substituted by one, two or three substituents independently selected from methyl and fluoro, or R5 is quinolinyl optionally substituted by one or two fluoro substituents. In a particular embodiment of the invention, R5 is indazol-5-yl substituted at the 1 position by a methyl substituent and optionally further substituted by one or two fluoro substituents, or R5 is quinolin-6-yl optionally substituted by one or two fluoro substituents. In an embodiment of the invention, said fluoro substituents are present at the 5 and/or 7 positions of the quinolinyl group. In a particular embodiment of the invention, R5 is quinolin-6-yl substituted by heterocyclyl2, or —C(CH3)═NO(C1-C3)alkyl, wherein the (C1-C3)alkyl of said C(CH3)═NO(C1-C3)alkyl is optionally substituted by one or more substituents independently selected from OH and halo wherein said heterocyclyl2 and —C(CH3)═NO(C1-C3)alkyl substituents are present at the 3-position of the quinolinyl group. In a further embodiment, R5 is quinolin-6-yl substituted by 3-(4-methylpiperazin-1-yl) or quinolin-6-yl substituted by 3-ethanone O-(2-hydroxy-ethyl)oxime. In a particular embodiment of the invention, R5 is 7-fluoro-quinolin-6-yl, quinolin-6-yl, 5,7-difluoroquinolin-6-yl, 1-methyl-1H-indazol-5-yl, 6-fluoro-1-methyl-1H-indazol-5-yl, 4,6-difluoro-1-methyl-1H-indazol-5-yl, 5-Fluoroquinolin-6-yl, 3-(4-methylpiperazin-1-yl)quinolin-6-yl or 6-quinolin-3-yl-ethanone O-(2-hydroxy-ethyl)oxime. In another embodiment of the invention, R6 is hydrogen, deuterium, OH or halo, particularly hydrogen, deuterium or halo, and in a preferred embodiment, R6 is hydrogen. In another embodiment of the invention, R7 is hydrogen, deuterium, halo, or methyl, wherein said methyl is optionally substituted by one or more substituents independently selected from OH and halo. In another embodiment of the invention R7 is hydrogen, deuterium, halo, or methyl. In a preferred embodiment, R7 is hydrogen or methyl, more preferably hydrogen. Where R1 is i, and R6 and R7 are not both hydrogen, the compound of formula (I) contains an asymmetric carbon nbrewer@example.org. Included within the scope of the invention is a compound of formula (I) containing the (R), or the (S) enantiomer of R1i, or a mixture thereof. In a preferred embodiment of the invention there is provided a compound of formula (I) containing the (S) enantiomer of R1i, or a mixture including the (S) enantiomer as a major component. In a preferred embodiment of the invention n is 0. In another embodiment of the invention, R2 is hydrogen or methyl. Preferably, R2 is methyl. In another embodiment of the invention, R3 is selected from: (C1-C6)alkyl, wherein said (C1-C6)alkyl is optionally substituted by one or more substituents independently selected from halo, hydroxy and (C1-C3)alkoxy, heterocyclyl1 phenyl, wherein said phenyl is optionally substituted by one or more substituents independently selected from halo, hydroxy, (C1-C3)alkyl and (C1-C3)alkoxy, wherein said (C1-C3)alkyl and (C1-C3)alkoxy are each optionally substituted by one or more halo substituents, —CH2— heterocyclyl1 —CH2-phenyl, wherein the phenyl of said —CH2-phenyl is optionally substituted by one or more substituents independently selected from halo, hydroxy, (C1-C3)alkyl and (C1-C3)alkoxy, wherein said (C1-C3)alkyl and (C1-C3)alkoxy are each optionally substituted by one or more halo substituents, (C1-C2)alkylCO2(C1-C2)alkyl, (C0-C2)alkylCONH2, (C1-C4)alkylNH2, (C1-C2)alkylNHCONH2, (C1-C2)alkylCO2H, (C1-C2)alkylNHCO2CH3, or Hydrogen, In another embodiment of the invention, R3 is selected from: (C1-C4)alkyl, wherein said (C1-C4)alkyl is optionally substituted by one or more substituents independently selected from halo, hydroxy and methoxy, pyrrolidinyl, optionally substituted by CONH2, piperidinyl, phenyl, wherein said phenyl is optionally substituted by one or more substituents independently selected from halo, hydroxy, (C1-C3)alkyl and (C1-C3)alkoxy, wherein said (C1-C3)alkyl and (C1-C3)alkoxy are each optionally substituted by one or more halo substituents, —CH2-pyrrolidinyl, wherein said pyrrolidinyl is optionally substituted by CONH2, —CH2-piperidinyl, —CH2-phenyl, wherein the phenyl of said —CH2-phenyl is optionally substituted by one or more substituents independently selected from halo, methyl and methoxy, wherein said methyl is optionally substituted by one, two or three halo substituents, (C1-C2)alkylCO2(C1-C2)alkyl, (C0-C2)alkylCONH2, (C2-C4)alkylNH2, (C1-C2)alkylNHCONH2, (C1-C2)alkylCO2H, oxetanyl (C1-C2)alkylNHCO2CH3, —CH2—(C3-C6)cycloalkyl, and hydrogen In a particular embodiment of the invention, R3 is ethyl, methyl, 2-hydroxyethyl, 1,3-dihydroxypropan-2-yl-, 2,3-dihydroxypropyl-, 2-hydroxy-1,1-dimethyl-ethyl-, 2-hydroxy-2-methyl-propyl-, pyrrolidin-3-yl-, -3-pyrrolidine-1-carboxamide, hydrogen, benzyl, 4-methoxybenzyl-, piperidin-4-yl-, piperidin-4-ylmethyl-, —CH2CO2CH3, —CH2CONH2, 2-aminoethyl-, 1-hydroxypropan-2-yl-, —CH2CH2NHCO2CH3, —CH2CH2NHCONH2; 3-trifluoromethylphenyl-, phenyl, 2-fluoroethyl-, 3-hydroxypropyl, 2-methoxyethyl, 4-hydroxybutyl, 4-fluorobutyl, CONH2, 1-hydroxy-2-methylpropan-2-yl, oxetan-3-yl or —CH2CO2H, cyclopropylmethyl, or hydrogen; In another particular embodiment of the invention, R3 is hydroxyethyl, particularly 2-hydroxyethyl, or hydrogen. In another embodiment there is provided a compound of formula (I) wherein Y is C or N; X is CH or N; B is CH or N; A is a ring; such that when X is CH and B is N, ring A is ring Ai or ring Aii; when X is N and B is N, ring A is Aiii; and when X is N and B is N, or X is N and B is CH, ring A is Ai; R1 is i: R5 is 7-fluoro-quinolin-6-yl, quinolin-6-yl, 5,7-difluoroquinolin-6-yl, 1-methyl-1H-indazol-5-yl, 6-fluoro-1-methyl-1H-indazol-5-yl, 4,6-difluoro-1-methyl-1H-indazol-5-yl, 5-fluoroquinolin-6-yl, (4-methylpiperazin-1-yl)quinolin-6-yl or 6-quinolin-3-yl-ethanone O-(2-hydroxy-ethyl)oxime R6 is hydrogen, deuterium, OH, methyl or halo; R7 is hydrogen, deuterium, halo, or (C1-C3)alkyl, wherein said (C1-C3)alkyl is optionally substituted by one or more substituents independently selected from OH and halo; or R6 and R7, together with the carbon to which they are attached form cyclopropyl; R2 is hydrogen, NH2, or (C1-C4)alkyl, and R3 is ethyl, methyl, 2-hydroxyethyl, 1,3-dihydroxypropan-2-yl-, 2,3-dihydroxypropyl-, 2-hydroxy-1,1-dimethyl-ethyl-, 2-hydroxy-2-methyl-propyl-, pyrrolidin-3-yl-, -3-pyrrolidine-1-carboxamide, hydrogen, benzyl, 4-methoxybenzyl-, piperidin-4-yl-, piperidin-4-ylmethyl-, —CH2CO2CH3, —CH2CONH2, 2-aminoethyl-, 1-hydroxypropan-2-yl-, —CH2CH2NHCO2CH3, —CH2CH2NHCONH2; 3-trifluoromethylphenyl-, phenyl, 2-fluoroethyl-, 3-hydroxypropyl, 2-methoxyethyl, 4-hydroxybutyl, 4-fluorobutyl, CONH2, 1-hydroxy-2-methylpropan-2-yl, oxetan-3-yl, hydrogen, cyclopropylmethyl, or —CH2CO2H; or a pharmaceutically acceptable salt thereof. In a further embodiment the invention provides a compound of formula (I) having a structure selected from (Ia), (Ib) or (Ic) above, wherein R1 is i: R5 is quinolin-6-yl optionally substituted by one or two fluoro substituents, the fluoro substituents being preferably in the 5 and/or 7 positions; R6 is hydrogen; R7 is hydrogen or methyl; R2 is methyl; and R3 is hydroxyethyl, more particularly 2-hydroxyethyl, or R3 is hydrogen; Various embodiments of the invention are described herein. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments. In a particular embodiment, the invention provides one or more compounds selected from the Example compounds disclosed herein, or a pharmaceutically acceptable salt thereof. FIG. 1 herein shows the X-ray diffractogram of Example 53S amorphous form. FIG. 2 shows the X-ray diffractogram of Example 53S crystalline form I. FIG. 3 shows the X-ray diffractogram of Example 53S crystalline form II. As used herein, the term “isomers” refers to different compounds that have the same molecular formula but differ in arrangement and configuration of the atoms. Also as used herein, the term “an optical isomer” or “a stereoisomer” refers to any of the various stereo isomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral center of a carbon atom. Therefore, the invention includes enantiomers, diastereomers or racemates of the compound. “Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a “racemic” mixture. The term is used to designate a racemic mixture where appropriate. “Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. The absolute stereochemistry is specified according to the Cahn-Ingold-Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S. Resolved compounds whose absolute configuration is unknown can be designated (+) or (−) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line. Certain of the compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-. The present invention is meant to include all such possible isomers, including racemic mixtures, optically pure forms and intermediate mixtures. Optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included. Any asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomerically enriched, for example the (R)-, (S)- or (R,S)-configuration, such as for the asymmetric carbon atom which may be present within the R1 group (i) defined herein. In certain embodiments, each asymmetric atom has at least 50% enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess in the (R)- or (S)-configuration. Preferably for the asymmetric R1 group (i) defined herein, the (S) enantiomer is in excess, in amounts as described above. Substituents at atoms with unsaturated bonds may, if possible, be present in cis-(Z)- or trans-(E)-form. Preferably, the hydrazones of the present invention have the trans-(E)-form. Accordingly, as used herein a compound of the present invention can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof. Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization. Any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. In particular, a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-O,O′-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid. Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent. Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, phosphorous, sulfur, chlorine, and iodine, such as 2H, 3H, 11C, 13C, 14C, 15N, 18F 31P, 32P, 35S, 36Cl, 125I respectively. Various isotopically labeled compounds of the present invention, for example those into which radioactive isotopes such as 3H, 13C, and 14C are incorporated. Such isotopically labelled compounds are useful in metabolic studies (preferably with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques [such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 18F or labeled compound may be particularly preferred for PET or SPECT studies. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a. readily available isotopically labeled reagent for a non-isotopically labeled reagent. Further, substitution with heavier isotopes, particularly deuterium (i.e., 2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index. It is understood that deuterium in this context is regarded as a substituent of a compound of the formula (I). The concentration of such a heavier isotope, specifically deuterium, may be defined by the isotopic enrichment factor. The term “isotopic enrichment factor” as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope. If a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation). In the compounds of this invention any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise stated, when a position is designated specifically as “H” or “hydrogen”, the position is understood to have hydrogen at its natural abundance isotopic composition. Accordingly, in the compounds of this invention any atom specifically designated as a deuterium (D) is meant to represent deuterium, for example in the ranges given above. Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed. As used herein, the term “pharmaceutically acceptable salts” refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable. The salt can be present alone or in mixture with free compound of the formula (I). In many cases, the compounds of the present invention are capable of forming acid salts by virtue of the presence of amino groups or groups similar thereto. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g., acetate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, chloride/hydrochloride, chlortheophyllonate, citrate, ethanedisulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, stearate, succinate, sulfosalicylate, tartrate, tosylate and trifluoroacetate salts. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table. In certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine. The pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound, a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable. Lists of additional suitable salts can be found, e.g., in “Remington's Pharmaceutical Sciences”, 20th ed., Mack Publishing Company, Easton, Pa., (1985); and in “Handbook of Pharmaceutical Salts: Properties, Selection, and Use” by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002). “Salts”, or “salts thereof” or “or a salt thereof”, can be present alone or in mixture with free compound of the formula (I). For isolation or purification purposes it is also possible to use pharmaceutically unacceptable salts, for example picrates or perchlorates. For therapeutic use, only pharmaceutically acceptable salts or free compounds are employed (where applicable in the form of pharmaceutical preparations), and these are therefore preferred. In view of the close relationship between the novel compounds in free form and those in the form of their salts, including those salts that can be used as intermediates, for example in the purification or identification of the novel compounds, any reference to the free compounds hereinbefore and hereinafter is to be understood as referring also to the corresponding salts, as appropriate and expedient. The compounds of the invention may exist in both unsolvated and solvated forms. The term ‘solvate’ is used herein to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term ‘hydrate’ is employed when said solvent is water. Pharmaceutically acceptable solvates include hydrates and other solvates wherein the solvent of crystallization may be isotopically substituted, e.g. D2O, d6-acetone, d6-DMSO. Any formula given herein is intended to represent hydrates, solvates, and polymorphs of such compounds, and mixtures thereof. Compounds of the invention, i.e. compounds of formula (I) that contain groups capable of acting as donors and/or acceptors for hydrogen bonds may be capable of forming co-crystals with suitable co-crystal formers. These co-crystals may be prepared from compounds of formula (I) by known co-crystal forming procedures. Such procedures include grinding, heating, co-subliming, co-melting, or contacting in solution compounds of formula (I) with the co-crystal former under crystallization conditions and isolating co-crystals thereby formed. Suitable co-crystal formers include those described in WO 2004/078163. Hence the invention further provides co-crystals comprising a compound of formula (I). The compounds of the invention therefore include compounds of formula I, polymorphs, and isomers thereof (including optical, geometric and tautomeric isomers) and isotopically-labelled compounds of formula I, as defined herein. In preferred embodiments, which are preferred independently, collectively or in any combination or sub-combination, the invention relates to a compound of the formula (I), in free base form or in acid addition salt form, wherein the substituents are as defined herein. The compounds of the present invention may be administered as prodrugs. Thus certain derivatives of compounds of formula (I) which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into compounds of formula (I) having the desired activity, for example, by hydrolytic cleavage. Such derivatives are referred to as ‘prodrugs’. [Further information on the use of prodrugs may be found in ‘Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T Higuchi and W Stella) and ‘Bioreversible Carriers in Drug Design’, Pergamon Press, 1987 (ed. E B Roche, American Pharmaceutical Association).] Prodrugs can, for example, be produced by replacing appropriate functionalities present in the compounds of formula (I) with certain moieties known to those skilled in the art as ‘pro-moieties’ as described, for example, in “Design of Prodrugs” by H Bundgaard (Elsevier, 1985). Some examples of such prodrugs include: (i) where the compound of formula (I) contains a carboxylic acid functionality (—COOH), an ester thereof, for example, replacement of the hydrogen with (C1-C8)alkyl; (ii) where the compound of formula (I) contains an alcohol functionality (—OH), an ether thereof, for example, replacement of the hydrogen with (C1-C6)alkanoyloxymethyl; and (iii) where the compound of formula (I) contains a primary or secondary amino functionality (—NH2 or —NHR where R≠H), an amide thereof, for example, replacement of one or both hydrogens with (C1-C10)alkanoyl. Certain compounds of formula (I) may also themselves act as prodrugs of other compounds of formula (I). The invention further relates to a pharmaceutically acceptable prodrug of a compound of formula (I). The invention further relates to a pharmaceutically acceptable metabolite of a compound of formula (I). “C-Met tyrosine kinase mediated diseases” are especially such disorders that respond in a beneficial way (e.g. amelioration of one or more symptoms, delay of the onset of a disease, up to temporary or complete cure from a disease) to the inhibition of a protein tyrosine kinase, especially inhibition of a c-Met kinase. These disorders include proliferative diseases such as tumor diseases, in particular solid tumors and metastasis derived thereof, e.g. hereditary papillary renal cell carcinoma (PRCC), sporadic forms of PRCC, head and neck cancer, squamous cell carcinoma, gastric carcinoma, pancreatic carcinoma, lung cancer, bladder cancer, breast cancer, leiomyosarcoma, glioblastoma, melanoma, alveolar soft part sarcoma. These disorders further include inflammatory conditions, such as inflammatory conditions due to an infection. “Combination” refers to either a fixed combination in one dosage unit form, or a kit of parts for the combined administration where a compound of the formula (I) and a combination partner (e.g. an other drug as explained below, also referred to as “therapeutic agent” or “co-agent”) may be administered independently at the same time or separately within time intervals, especially where these time intervals allow that the combination partners show a cooperative, e.g. synergistic effect. The terms “co-administration” or “combined administration” or the like as utilized herein are meant to encompass administration of the selected combination partner to a single subject in need thereof (e.g. a patient), and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time. The term “pharmaceutical combination” as used herein means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients. The term “fixed combination” means that the active ingredients, e.g. a compound of formula (I) and a combination partner, are both administered to a patient simultaneously in the form of a single entity or dosage. The term “non-fixed combination” means that the active ingredients, e.g. a compound of formula (I) and a combination partner, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the two compounds in the body of the patient. The latter also applies to cocktail therapy, e.g. the administration of three or more active ingredients. The invention relates especially to a compound of the formula (I) as provided in the Examples, as well as the methods of manufacture described therein. The compounds of formula (I) have valuable pharmacological properties, as described hereinbefore and hereinafter. In another embodiment of the invention, there is provided a method for treating a c-Met related disorder or condition. The disorder or condition to be treated is preferably a proliferative disease such as a cancer or an inflammatory condition. Compounds of formula (I) are further useful for treating diseases associated with a c-Met-related condition. A: Proliferative Diseases: Compounds of Formula (I) are Particular Useful for the Treatment of One or More of the Following Proliferative Diseases: Compounds of formula (I) are useful in the treatment of cancer wherein the cancer is selected from the group consisting of brain cancer, stomach cancer, genital cancer, urinary cancer, prostate cancer, bladder cancer (superficial and muscle invasive), breast cancer, cervical cancer, colon cancer, colorectal cancer, glioma (including glioblastoma, anaplastic astrocytoma, oligoastrocytoma, oligodendroglioma), esophageal cancer, gastric cancer, gastrointestinal cancer, liver cancer, hepatocellular carcinoma (HCC) including childhood HCC, head and neck cancer (including head and neck squamous-cell carcinoma, nasopharyngeal carcinoma), Hurthle cell carcinoma, epithelial cancer, skin cancer, melanoma (including malignant melanoma), mesothelioma, lymphoma, myeloma (including multiple myeloma), leukemias, lung cancer (including non-small cell lung cancer (including all histological subtypes: adenocarcinoma, squamous cell carcinoma, bronchoalveolar carcinoma, large-cell carcinoma, and adenosquamous mixed type), small-cell lung cancer), ovarian cancer, pancreatic cancer, prostate cancer, kidney cancer (including but not limited to papillary renal cell carcinoma), intestine cancer, renal cell cancer (including hereditary and sporadic papillary renal cell cancer, Type I and Type II, and clear cell renal cell cancer); sarcomas, in particular osteosarcomas, clear cell sarcomas, and soft tissue sarcomas (including alveolar and embryonal rhabdomyosarcomas, alveolar soft part sarcomas); and thyroid carcinoma (papillary and other subtypes). Compounds of formula (I) are useful in the treatment of cancer wherein the cancer is stomach, colon, liver, genital, urinary, melanoma, or prostate. In a particular embodiment, the cancer is liver or esophageal. Compounds of formula (I) are useful in the treatment of colon cancer, including metastases, e.g. in the liver, and of non-small-cell lung carcinoma. Compounds of formula (I) may also be used in the treatment of hereditary papillary renal carcinoma (Schmidt, L. et al. Nat. Genet. 16, 68-73, 1997) and other proliferative diseases in which c-Met is overexpressed or constitutively activated by mutations (Jeffers and Vande Woude. Oncogene 18, 5120-5125, 1999; and reference cited therein) or chromosomal rearrangements (e.g. TPR-MET; Cooper et al. Nature 311, 29-33, 1984; Park. et al. Cell 45, 895-904, 1986). Compounds of formula (I) are further useful in the treatment of additional cancers and conditions as provided herein or known in the art. B: Inflammatory Conditions: Compounds of Formula (I) are Particular Suitable for the Treatment of One or More Inflammatory Conditions. In a further embodiment, the inflammatory condition is due to an infection. In one embodiment, the method of treatment would be to block pathogen infection. In a particular embodiment, the infection is a bacterial infection, e.g., a Listeria infection. See, e.g., Shen et al. Cell 103: 501-10, (2000) whereby a bacterial surface protein activates c-Met kinase through binding to the extracellular domain of the receptor, thereby mimicking the effect of the cognate ligand HGF/SF. Compounds of formula (I) are further useful in the treatment of additional inflammatory disorders and conditions as provided herein or known in the art. C: Combination Therapy: in Certain Embodiments, any of the Above Methods Involve Further Administering a Chemotherapeutic Agent. In a related embodiment, the chemotherapeutic agent is an anti-cancer agent. Specific combinations are provided throughout the application. In a further related embodiment, any of the above methods involve further administering a pathway specific inhibitor. The pathway specific inhibitor may be a chemotherapeutic agent or may be a biologic agent, e.g., antibodies. Pathway specific inhibitors include, but are not limited to, inhibitors of EGFR, Her-2, Her-3, VEGFR, Ron, IGF-IR, PI-3K, mTOR, and Raf. In a further related embodiment to several of the above methods, following administering to the subject or contacting the cell, these methods can further involve observing amelioration or retardation of development or metastasis of the cancer. Thus, in one embodiment, the invention relates to a method of treating a c-Met related disorder or condition which involves administering to a subject in need thereof an effective amount of a compound of formula (I). In a further embodiment, the invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a medicament, in particular for the treatment of one or more C-Met tyrosine kinase mediated diseases. In a further embodiment, the invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of one or more C-Met tyrosine kinase mediated diseases. In a further embodiment, the invention relates to a method for the treatment of a disease or disorder which responds to an inhibition of C-Met tyrosine kinase, which comprises administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, especially in a quantity effective against said disease, to a warm-blooded animal requiring such treatment. In a further embodiment, the invention relates to a pharmaceutical composition comprising a compound of formula (I) as active ingredient in association with at least one pharmaceutical carrier or diluent. In a further embodiment, the invention relates to a pharmaceutical composition comprising: (a) an effective amount of compound of formula (I) and pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and/or pharmaceutically active metabolites thereof; and (b) one or more pharmaceutically acceptable excipients and/or diluents. In a further embodiment, the invention relates to a pharmaceutical composition for treatment of a disease, e.g. of solid or liquid tumours in warm-blooded animals, including humans, comprising a dose effective in the treatment of said disease of a compound of the formula (I) as described above or a pharmaceutically acceptable salt of such a compound together with a pharmaceutically acceptable carrier (=carrier material). In another embodiment of the invention, there is provided a pharmaceutical preparation (composition), comprising a compound of formula (I) as defined herein, or a pharmaceutically acceptable salt of such a compound, or a hydrate or solvate thereof, and at least one pharmaceutically acceptable carrier and/or diluents and optionally one or more further therapeutic agents. As used herein, the term “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated. The term “a therapeutically effective amount” of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc. In one non-limiting embodiment, the term “a therapeutically effective amount” refers to the amount of the compound of the present invention that, when administered to a subject, is effective to (1) at least partially alleviating, inhibiting, preventing and/or ameliorating a condition, or a disorder or a disease (i) mediated by c-Met or (ii) associated with c-Met activity, or (iii) characterized by activity (normal or abnormal) of c-Met; or (2) reducing or inhibiting the activity of c-Met; or (3) reducing or inhibiting the expression of c-Met. In another non-limiting embodiment, the term “a therapeutically effective amount” refers to the amount of the compound of the present invention that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of c-Met; or at least partially reducing or inhibiting the expression of c-Met. As used herein, the term “subject” refers to an animal. Typically the animal is a mammal. A subject also refers to for example, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human. As used herein, the term “inhibit”, “inhibition” or “inhibiting” refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process. As used herein, the term “treat”, “treating” or “treatment” of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treat”, “treating” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient. In yet another embodiment, “treat”, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, “treat”, “treating” or “treatment” refers to preventing or delaying the onset or development or progression of the disease or disorder. As used herein, a subject is “in need of” a treatment if such subject would benefit biologically, medically or in quality of life from such treatment. As used herein, the term “a,” “an,” “the” and similar terms used in the context of the present invention (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context. In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier. The pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration, and rectal administration, etc. In addition, the pharmaceutical compositions of the present invention can be made up in a solid form (including without limitation capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including without limitation solutions, suspensions or emulsions). The pharmaceutical compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers and buffers, etc. Typically, the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; if desired d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners. Tablets may be either film coated or enteric coated according to methods known in the art. Suitable compositions for oral administration include an effective amount of a compound of the invention in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil. Certain injectable compositions are aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, or contain about 1-50%, of the active ingredient. Suitable compositions for transdermal application include an effective amount of a compound of the invention with a suitable carrier. Carriers suitable for transdermal delivery include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin. Suitable compositions for topical application, e.g., to the skin and eyes, include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, e.g., for delivery by aerosol or the like. Such topical delivery systems will in particular be appropriate for
{'application_number': '<application-reference appl-type="utility">\n<document-id>\n<country>US</country>\n<doc-number>12859653</doc-number>\n<date>20100819</date>\n</document-id>\n</application-reference>', 'publication_number': '<publication-reference>\n<document-id>\n<country>US</country>\n<doc-number>20110065708</doc-number>\n<kind>A1</kind>\n<date>20110317</date>\n</document-id>\n</publication-reference>', 'source_file': './application/2011/ipa110317.xml', 'source_data': 'USPTO-Application'}